PGEN.US Precigen Inc

Healthcare Biotechnology USA Stocks
4.30 USD
Close of Nov 17, 2026
3.04 8.98
Market cap
USD 1.54B
P/E
39.1x
P/B
19.36x
ROE
76.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PGEN.US undervalued?

Graham number

The Graham number of Precigen Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Precigen Inc fundamental analysis

No fundamental analysis for Precigen Inc yet.

Precigen Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Precigen Inc

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric anti…

Full company profile